Acute promyelocytic leukemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
No edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Acute promyelocytic leukemia}} | {{Acute promyelocytic leukemia}} | ||
{{CMG}} {{shyam}} | {{CMG}}; {{AE}} {{shyam}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
A limited number of cost-effective studies have been done. In summary, these studies showed that all-''trans'' retinoic acid-based therapy is more cost effective than chemotherapy. | A limited number of cost-effective studies have been done. In summary, these studies showed that all-''[[trans]]'' [[retinoic acid]]-based [[therapy]] is more cost effective than [[chemotherapy]]. | ||
==Cost-effectiveness of therapy== | ==Cost-effectiveness of therapy== | ||
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy. | A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective [[analysis]] studied the costs of [[therapy]]. | ||
*The combination of all-''trans'' retinoic acid plus idarubicin was more cost-effective than the combination of all-''trans'' retinoic acid plus cytarabine plus additional chemotherapy.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | *The combination of all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]] was more cost-effective than the combination of all-''[[trans]]'' [[retinoic acid]] plus [[cytarabine]] plus additional [[chemotherapy]].<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | ||
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | **The [[Incremental cost-effectiveness ratio|incremental cost-effective ratio]] for all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]] was $2933 per life year saved and $3122 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | ||
*The combination of all-''trans'' retinoic acid plus arsenic trioxide was more cost-effective than all-''trans'' retinoic acid plus idarubicin.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | *The combination of all-''[[trans]]'' [[retinoic acid]] plus [[arsenic]] trioxide was more cost-effective than all-''[[trans]]'' [[retinoic acid]] plus [[idarubicin]].<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | ||
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | **The [[incremental cost-effective ratio]] for all-''[[trans]]'' [[retinoic acid]] plus [[arsenic trioxide]] was $4512 per life year saved and $5614 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 13:13, 11 April 2019
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia cost-effectiveness of therapy |
|
FDA on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
CDC on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Acute promyelocytic leukemia cost-effectiveness of therapy in the news |
|
Blogs on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
A limited number of cost-effective studies have been done. In summary, these studies showed that all-trans retinoic acid-based therapy is more cost effective than chemotherapy.
Cost-effectiveness of therapy
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.
- The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
- The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.